WNT-PD-001: A multi-phase preclinical and clinical study to validate the Wnt-Beta-Catenin Signaling Dysfunction Hypothesis in Parkinson's Disease.
Impaired Wnt/beta-catenin signaling contributes to dopaminergic neuron degeneration through disrupted developmental maintenance, mitochondrial dysfunction, neuroinflammation amplification, and accelerated alpha-synuclein aggregation.
| Parameter |
Details |
| Model |
iPSC-derived dopaminergic neurons from PD patients (n=3-5 lines) vs. healthy controls (n=3-5 lines) |
| Measurements |
Wnt3a secretion, beta-catenin nuclear translocation, TCF/LEF reporter activity |
| Controls |
Age-matched healthy controls, LRRK2 G2019S carriers vs. idiopathic PD |
| Endpoints |
Wnt ligand levels, beta-catenin localization, pathway transcriptional activity |
| Parameter |
Details |
| Model |
iPSC-derived dopaminergic neurons |
| Interventions |
Wnt3a treatment (100 ng/mL), GSK3beta inhibition (CHIR99021, 1 μM) |
| Measurements |
Complex I activity, mitochondrial membrane potential (TMRE), ATP production, mtDNA copy number |
| Endpoints |
Mitochondrial respiration (Seahorse), ROS production (MitoSOX) |
| Parameter |
Details |
| Model |
iPSC-derived dopaminergic neurons with SNCA A53T mutation |
| Interventions |
Wnt3a treatment, Wnt3a + alpha-synuclein siRNA |
| Measurements |
Alpha-synuclein aggregation (pSer129), autophagy markers (LC3II, p62), Wnt target gene expression |
| Endpoints |
Alpha-synuclein phosphorylation, autophagic flux, protein clearance rates |
| Parameter |
Details |
| Model |
C57BL/6 mice, MPTP-induced PD model; Thy1-SNCA transgenic mice |
| Groups |
(1) Vehicle control, (2) MPTP + Wnt3a (intranasal 10 μg/day), (3) MPTP + CHIR99021 (25 mg/kg/day ip), (4) MPTP + combination |
| Duration |
4 weeks MPTP + 4 weeks treatment |
| Endpoints |
Behavioral testing (rotarod, cylinder, gait analysis), dopaminergic neuron survival (TH+ counts), pathway markers |
| Parameter |
Details |
| Measurements |
Beta-catenin nuclear translocation, TCF/LEF reporter activity, mitochondrial markers, neuroinflammation markers (Iba1, GFAP), alpha-synuclein aggregation |
| Tissues |
Substantia nigra, striatum, cortex |
| Methods |
Western blot, immunohistochemistry, qPCR |
| Parameter |
Details |
| Cohort |
PD patients (n=100) vs. healthy controls (n=50) |
| Samples |
CSF, plasma, peripheral blood mononuclear cells (PBMCs) |
| Biomarkers |
Wnt3a (ELISA), beta-catenin (Western blot), GSK3beta activity, Axin2 expression (qPCR in PBMCs) |
| Clinical measures |
UPDRS, MoCA, disease duration, Hoehn & Yahr stage |
| Parameter |
Details |
| Design |
Randomized, double-blind, placebo-controlled |
| Cohort |
Early-stage PD patients (n=60, 30 per arm) |
| Intervention |
Lithium carbonate 300mg daily vs. placebo for 12 weeks |
| Endpoints |
CSF Wnt pathway markers, UPDRS, safety profile |
| Background |
Previous trial data suggesting lithium safety in older adults |
- Wnt Pathway Activity: Reduced nuclear beta-catenin and TCF/LEF activity in PD patient neurons vs. controls
- Mitochondrial Function: Correlation between Wnt pathway activity and complex I activity
- Neuroprotection: Improved dopaminergic neuron survival with Wnt pathway activation in vivo
- Biomarker Correlation: Wnt pathway biomarkers correlate with clinical severity in PD patients
- Alpha-Synuclein: Wnt activation reduces pSer129 alpha-synuclein in patient neurons
- Neuroinflammation: Wnt pathway modulation reduces microglial activation markers
- Clinical Correlation: Wnt biomarker levels predict disease progression rate
- Safety: Lithium and Wnt modulators show acceptable safety profile in PD patients
- Sample Size: Power 80% to detect 30% difference in Wnt pathway markers (alpha=0.05)
- Methods: ANOVA with post-hoc corrections, linear mixed models for longitudinal data
- Multiple Comparison Correction: FDR < 0.05 for biomarker panels
- Correlations: Pearson correlation between biomarkers and clinical measures
- Phase 1: PD patient neurons show 40-60% reduced Wnt pathway activity
- Phase 2: Wnt pathway activation provides 30-50% neuroprotection in mouse models
- Phase 3: Wnt biomarkers distinguish PD patients from controls (AUC > 0.85)
| Risk |
Mitigation |
| Wnt pathway overactivation (tumor risk) |
Use physiological doses, monitoring |
| Lithium side effects |
Low dose, therapeutic drug monitoring |
| BBB permeability of Wnt ligands |
Intranasal delivery, BBB-penetrant small molecules |
| Off-target effects |
Targeted delivery, selective agonists |
| Phase |
Estimated Cost |
| Phase 1 (In Vitro) |
$150,000 |
| Phase 2 (In Vivo) |
$250,000 |
| Phase 3 (Clinical) |
$400,000 |
| Total |
$800,000 |
Month 1-6: Phase 1 - In vitro validation
Month 6-12: Phase 2 - In vivo validation
Month 12-18: Phase 3 - Clinical biomarker study
Month 18-24: Analysis and publication
- Zhang et al., Wnt/beta-catenin signaling in Parkinson's disease (2023)
- Inden et al., Lithium protects dopaminergic neurons in PD models (2021)
- Matsuda et al., Wnt3a neuroprotection in MPTP model (2019)